Despite a 30% cap on trade margins for non-scheduled cancer drugs, prices for branded cancer medications remain unchanged, ...

Despite a $2.2 billion setback due to failed drug trials, Novartis raises its profit forecast for the year, highlighting ...

The FDA has cautioned Amgen about a promotional video for Vectibix, its colorectal cancer drug, which allegedly ...

The CDSCO has raised a public alert regarding a counterfeit batch of the liver medication Defitelio, prompting patients to ...

India's drug regulator DCGI cancels the import registration of FatX, a cosmetic product marketed with unauthorized ...

Eli Lilly reveals significant leadership transitions as Patrik Jonsson announces retirement and Ilya Yuffa steps into the ...

Cipla's bispecific ADC rolditamig deruxtecan demonstrates a remarkable 71% reduction in disease progression for late-stage ...

Cipla targets a first wave launch of its Keytruda biosimilar QL2107 in the US after patent expiry in 2029, with expectations ...

OneSource Specialty Pharma has reported a staggering 109% year-on-year increase in Q2 net profit for the second quarter ...

Mankind Pharma's net profit rises to ₹716 crore for Q2 FY27, driven by strong sales growth while seeking transformation in ...

Hengrui Pharmaceuticals, China's leading drugmaker, reported an impressive 88.9% increase in net profit for Q3 2026, driven ...

GSK is planning to nearly double the number of cancer medicines in clinical trials next year, part of a strategy to address a ...